paul hudson sanofi email address

I wonder would you, if you could comment whether there’s any change in your thinking regarding that combination in solid tumors and also an update perhaps on the use of Sarclisa in some of your other combinations and whether or not there’s any data or insights you got from that study at all that I have any other implications? Please go ahead. The new Sanofi CEO is Paul Hudson. I will leave you to read the details and in the interest of time, I’ll just point you to a couple of highlights. Connecting decision … But the former Novartis executive emphasized to reporters Tuesday he views his job as helping the company be better at … Can you hear us, John? And then secondly, just on Sarclisa. So, as you know, there has been a theory that CD38, the target of Sarclisa might have a broader role to play as immune checkpoint and so that was the hypothesis that we were testing in these combination studies and did small signal seeking studies across eight indications. I hope everybody gets a little bit of a break and thank you to everybody that joined on the call. The next question comes from the line of Graham Parry with Bank of America. We also indicated that we will continue to externally add to our pipeline if we can find transformative medicines in areas for us to focus in Specialty Care and Vaccines, which meets these four key areas of differentiation. PharmaTimes Media Ltd. We achieved an important regulatory milestone in the quarter, both for our Sanofi China strategy and for the Dupixent franchise with the approval in adult AD in China. So, we feel, we don’t have to do anything more different to that to outperform and build something quite special in terms of financially capabilities and scientifically, in reverse order. Excluding these benefits, we still delivered a strong underlying performance, and I remain fully confident we will meet our target to improve free cash flow by 50% by 2022. And we want to start the Phase III I believe in the first half of December of 2020. Second quarter was a strong quarter across all three main indications, with 70% growth globally, and we added more than EUR 80 million sales versus the prior quarter, and sales annualizing at close to EUR 3.5 billion already. I think secondly, a quick read, and there is not a great load of detail as you’ll imagine, but a quick read is that it may be more towards Part B where the challenges may be. And then maybe to confirm today that as soon as possibility is not anymore in January, 2021, but in December, 2020, we are aiming to further accelerate the vaccines. Our entire specialty business has been very resilient and continues to grow. So I may toss it to Bill if he’s connected. And that means that we hold the wheel firmly of Sanofi and that we will not get derailed easily, and that’s the main message, really. As usual, you can find the slides to this call on the Investors page of our website at sanofi.com. Ned Pagliarulo And the second question is the elephant in the room about U.S. health care reform. And therefore, we want to make sure that the way we will do it will be in a sustainable way moving forward. But Jean-Baptiste, any comment on the investment level through Q2 in Dupixent? So, COVID-19 price, if I understood correctly the question. Both the AZ and the Roche compounds have shown profiles with their own individual challenges that could mean that the tolerability of these compounds may not be suitable for this hormone receptor-positive breast cancer population. When you’re adding specialty capability, the marginal cost is much lower. For years a diabetes company first, Sanofi has more recently sought to establish itself as a larger player in cancer, immunology and rare blood disorders like hemophilia. In diabetes, the single-digit decline in glargine moderated due to solid overall growth in the rest of the world. We also say a fond au revoir to Olivier Brandicourt, who is retiring. And if not, when do you expect it? And we continue to strengthen our leadership in select therapeutic areas with several transactions this quarter, and we’ll touch on those a little bit later. French language lessons are scheduled for everyone, including Paul, who is a British national. The second part of your question, if I understood correctly, was about will there be a shortage? It’s not like we’re adding primary care field forces. We feel as though these are all important investments to drive what this brand can become. Thanks, Bill, on that. Thank you to Eva, very happy to have you on the team and leading IR. First of all back to the actual the regimen, I would say, and the need for an adjuvant without them telling you to the details of the Phase I, Phase II study, that we tend to start early part of September, and that’s looking good from maintaining that perspective. To General Medicine, this is where we face the biggest impact from the ongoing pandemic with a sales decline of 12.7% in the quarter, and since we had some positive stocking effects in Q1, a decline of 8.2% in H1. The Next question comes from the line of Wimal Kapadia with Bernstein. But overall, again, the vast majority will come from volume also. Partly as a result, U.S. sales of Sanofi's diabetes products declined nearly 18% year over year in the three months from April to June, weighing on the company's growth elsewhere. Please go ahead. Since 2018, we have cut a number of our product families by close to a third to around 220, and our target is to reduce this to around 100 by 2025. Yes. Please go ahead. You can also see that we have cut our tertiary size by a third. And as always, if there’s some stimulus, maybe something good also can come from it. So consequently, we still expect our annual R&D budget to trend towards the EUR 6 billion figure we have previously highlighted.

Raheem Mostert Injury, Peggy Carter, Hilarie Burton Husband, Goodreads Book Reviews Recommendations And Discussion, Sam Elliott Voice Over Commercials For Trump,